Drug Search Results
More Filters [+]

Bismuth subsalicylate

Alternative Names: bismuth subsalicylate, PEPTO-BISMOL, PEPTO BISMOL, helidac, helidac therapy
Latest Update: 2024-06-28
Latest Update Note: Clinical Trial Update

Product Description

Bismuth subsalicylate is used to treat diarrhea, heartburn, and upset stomach in adults and children 12 years of age and older. Bismuth subsalicylate is in a class of medications called antidiarrheal agents. It works by decreasing the flow of fluids and electrolytes into the bowel, reduces inflammation within the intestine, and may kill the organisms that can cause diarrhea. (Sourced from: https://medlineplus.gov/druginfo/meds/a607040.html)

Mechanisms of Action: PG Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Bangladesh | Brazil | Canada | Chile | China | Colombia | Dominican Republic | Ecuador | Hungary | Indonesia | Jordan | Malta | Mexico | New Zealand | Pakistan | Peru | Philippines | Russia | Taiwan | Thailand | Turkey | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Bismuth subsalicylate

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events